Active Biotech 
Welcome,         Profile    Billing    Logout  
 6 Products   58 Diseases  6 Products   7 Trials   587 News 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RhuDex (AV 1142742) / Dr Falk, Medigene
2020-001961-34: Clinical trial comparing the efficacy and safety of Rhudex granules with placebo in the treatment of the liver disease Primary Biliary Cholangitis

Ongoing
2
136
Europe
RhuDex 25 mg (31.75 mg RhuDex choline salt) granules, RhuDex 50 mg (63.5 mg RhuDex choline salt) granules, RhuDex 100 mg (127 mg RhuDex choline salt) granules, Granules
Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH
Primary biliary cholangitis, A type of long-term liver disease in which the bile ducts in the liver become damaged., Diseases [C] - Immune System Diseases [C20]
 
 
Anyara (naptumomab estafenatox) / NeoTX
NT-NAP-102-1, NCT04880863: NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Completed
2
38
US
NAP (Naptumomab estafenatox), ABR-217620, Anyara, Docetaxel, Taxotere, Obinutuzumab, Gazyva
NeoTX Therapeutics Ltd., Translational Drug Development
Non-small Cell Lung Cancer
01/24
01/24
NCT05894447: Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Withdrawn
1
30
US
Naptumomab Estafenatox, Pembrolizumab, Keytruda, Obinutuzumab, Gazyva
Weill Medical College of Cornell University, NeoTX Therapeutics Ltd.
Urothelial Carcinoma
12/25
06/28
NCT03983954: Naptumomab Estafenatox in Combination with Durvalumab in Subjects with Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Hourglass Jan 2021 - Mar 2021 : First safety data from P1b trial in combination with Imfinzi for solid tumors
Hourglass Oct 2020 - Dec 2020 : Completion of P1b portion of p1b/2 trial in combination with Imfinzi for solid tumors
Recruiting
1
120
RoW
Obinutuzumab, naptumomab estafenatox and durvalumab, (ABR-217620; NAP), (IMFINZI; MEDI4736), [Gazyva], Naptumomab estafenatox and durvalumab
NeoTX Therapeutics Ltd., AstraZeneca
ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation, Esophageal Cancer
03/27
03/27
tasquinimod (ABR-215050) / Active Biotech, Ipsen
ACTRN12621000016831p: Effect of Tasquinimod on COVID-19 patients

Not yet recruiting
2
125
 
Hunter medical research institute, Hunter medical research institute
COVID-19
 
 
NCT06327100: Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Recruiting
2
33
US
Ruxolitinib, Jakafi, INCB018424, INC424, Tasquinimod
M.D. Anderson Cancer Center, Active Biotech AB
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
05/29
05/31
HOVON 172 MF, NCT06605586: Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

Recruiting
1/2
20
Europe
Tasquinimod
Stichting Hemato-Oncologie voor Volwassenen Nederland
Myelofibrosis
12/27
03/30
NCT04405167: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Active, not recruiting
1
34
US
Tasquinimod, IRd chemotherapy, Ixazomib, Lenalidomide, Dexamethasone
University of Pennsylvania, Active Biotech AB
Multiple Myeloma
07/25
07/26
laquinimod topical (TV-5600) / Active Biotech
LION, NCT06161415: Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The Study

Recruiting
1
12
US
Laquinimod eye drops, LAQ eye drops
Quan Dong Nguyen, Global Ophthalmic Research Center (GORC)
Inflammation, Uveitis
07/25
07/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RhuDex (AV 1142742) / Dr Falk, Medigene
2020-001961-34: Clinical trial comparing the efficacy and safety of Rhudex granules with placebo in the treatment of the liver disease Primary Biliary Cholangitis

Ongoing
2
136
Europe
RhuDex 25 mg (31.75 mg RhuDex choline salt) granules, RhuDex 50 mg (63.5 mg RhuDex choline salt) granules, RhuDex 100 mg (127 mg RhuDex choline salt) granules, Granules
Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH
Primary biliary cholangitis, A type of long-term liver disease in which the bile ducts in the liver become damaged., Diseases [C] - Immune System Diseases [C20]
 
 
Anyara (naptumomab estafenatox) / NeoTX
NT-NAP-102-1, NCT04880863: NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Completed
2
38
US
NAP (Naptumomab estafenatox), ABR-217620, Anyara, Docetaxel, Taxotere, Obinutuzumab, Gazyva
NeoTX Therapeutics Ltd., Translational Drug Development
Non-small Cell Lung Cancer
01/24
01/24
NCT05894447: Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Withdrawn
1
30
US
Naptumomab Estafenatox, Pembrolizumab, Keytruda, Obinutuzumab, Gazyva
Weill Medical College of Cornell University, NeoTX Therapeutics Ltd.
Urothelial Carcinoma
12/25
06/28
NCT03983954: Naptumomab Estafenatox in Combination with Durvalumab in Subjects with Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Hourglass Jan 2021 - Mar 2021 : First safety data from P1b trial in combination with Imfinzi for solid tumors
Hourglass Oct 2020 - Dec 2020 : Completion of P1b portion of p1b/2 trial in combination with Imfinzi for solid tumors
Recruiting
1
120
RoW
Obinutuzumab, naptumomab estafenatox and durvalumab, (ABR-217620; NAP), (IMFINZI; MEDI4736), [Gazyva], Naptumomab estafenatox and durvalumab
NeoTX Therapeutics Ltd., AstraZeneca
ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation, Esophageal Cancer
03/27
03/27
tasquinimod (ABR-215050) / Active Biotech, Ipsen
ACTRN12621000016831p: Effect of Tasquinimod on COVID-19 patients

Not yet recruiting
2
125
 
Hunter medical research institute, Hunter medical research institute
COVID-19
 
 
NCT06327100: Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Recruiting
2
33
US
Ruxolitinib, Jakafi, INCB018424, INC424, Tasquinimod
M.D. Anderson Cancer Center, Active Biotech AB
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
05/29
05/31
HOVON 172 MF, NCT06605586: Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

Recruiting
1/2
20
Europe
Tasquinimod
Stichting Hemato-Oncologie voor Volwassenen Nederland
Myelofibrosis
12/27
03/30
NCT04405167: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Active, not recruiting
1
34
US
Tasquinimod, IRd chemotherapy, Ixazomib, Lenalidomide, Dexamethasone
University of Pennsylvania, Active Biotech AB
Multiple Myeloma
07/25
07/26
laquinimod topical (TV-5600) / Active Biotech
LION, NCT06161415: Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The Study

Recruiting
1
12
US
Laquinimod eye drops, LAQ eye drops
Quan Dong Nguyen, Global Ophthalmic Research Center (GORC)
Inflammation, Uveitis
07/25
07/25

Download Options